Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Obstet Gynecol ; 180(6 Pt 1): 1543-50, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10368502

ABSTRACT

OBJECTIVE: Our purpose was to compare the efficacy and safety of misoprostol with dinoprostone (Prepidil) for labor induction. STUDY DESIGN: In a randomized, controlled trial of labor induction, patients were randomly assigned to receive either 50 microgram of intravaginal misoprostol every 4 hours or 0.5 mg of intracervical prostaglandin E2 every 6 hours. Eligibility criteria included gestation of >/=31 weeks, Bishop score <6, and fewer than 12 contractions per hour. Primary outcomes were cesarean section, induction to delivery time, oxytocin use, and fetal distress requiring delivery. RESULTS: One hundred fifty-nine women were randomly assigned to receive misoprostol (n = 81) or Prepidil (n = 78). There were no differences in the indication for induction, preinduction Bishop score, epidural use, or cesarean section rate. Mean time to delivery was significantly shorter in the misoprostol group (19 hours 50 minutes) than in the Prepidil group (28 hours 52 minutes) (P =.005). Only 58% of women in the misoprostol group required oxytocin augmentation, in comparison with 88% of women receiving Prepidil (P =.00002). However, 41% of women receiving misoprostol and 17% receiving Prepidil had late decelerations or bradycardias (P =.001), and 20% of the misoprostol group and 5% of the Prepidil group had deliveries for fetal distress (P =.05). CONCLUSIONS: Misoprostol is more efficacious than Prepidil for labor induction. However, the significantly increased incidence of abnormal fetal heart rate tracings and the trend in increased deliveries for fetal distress with misoprostol dosing of 50 microgram every 4 hours are of concern. These data suggest that either a lower dose of misoprostol or less frequent dosing of misoprostol should be considered.


Subject(s)
Dinoprostone/therapeutic use , Labor, Induced , Misoprostol/adverse effects , Misoprostol/therapeutic use , Oxytocics/therapeutic use , Administration, Intravaginal , Adult , Bradycardia/epidemiology , Cesarean Section , Dinoprostone/administration & dosage , Dinoprostone/adverse effects , Female , Fetal Distress/epidemiology , Heart Rate, Fetal , Humans , Intensive Care, Neonatal , Misoprostol/administration & dosage , Oxytocics/adverse effects , Pregnancy , Risk Factors , Time Factors
2.
Am J Obstet Gynecol ; 177(1): 37-41, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9240580

ABSTRACT

OBJECTIVE: Our purpose was to determine the incidence of birth injury in a cohort of macrosomic infants (birth weight >4000 gm) and analyze the association between persistent injury and delivery method. STUDY DESIGN: Deliveries of 2924 macrosomic infants were reviewed. Outcomes were compared with those of 16,711 infants with birth weights between 3000 and 3999 gm. RESULTS: Macrosomic infants had a sixfold increase in significant injury relative to controls (relative risk 6.7,95% confidence interval 6.5 to 6.9). Risk of trauma correlated with delivery mode: forceps were associated with a fourfold risk of clinically persistent findings compared with spontaneous vaginal delivery or cesarean section. However, the overall incidence of persistent cases remained low (0.3%); a policy of elective cesarean section for macrosomia would necessitate 148 to 258 cesarean sections to prevent a single persistent injury. Avoidance of operative vaginal delivery would require 50 to 99 cesarean sections per injury prevented. CONCLUSIONS: These findings support a trial of labor and judicious operative vaginal delivery for macrosomic infants.


Subject(s)
Birth Injuries/epidemiology , Birth Injuries/etiology , Cesarean Section/adverse effects , Delivery, Obstetric/adverse effects , Extraction, Obstetrical/adverse effects , Fetal Macrosomia/complications , Birth Injuries/prevention & control , Birth Weight/physiology , Cohort Studies , Female , Fetal Macrosomia/physiopathology , Humans , Incidence , Infant, Newborn , Pregnancy , Pregnancy Outcome , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...